欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

EGFR

EGFR

货号 产品名 CAS号 信息
CSN16551 WZ8040 1214265-57-2 WZ8040 is a mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).
CSN16109 WZ4002 1213269-23-8 WZ4002 is an irreversible inhibitor of mutant EGFR (L858R) and EGFR (T790M) with IC50 of 2 nM and 8 nM respectively.
CSN16526 WZ-3146 1214265-56-1 WZ3146 is a mutant-selective irreversible inhibitor of EGFR (L858R) and EGFR (E746_A750) with IC50 of 2 nM and 2 nM and does not inhibit ERBB2 phosphorylation (T798I).
CSN20619 Tyrphostin RG 14620 136831-49-7 Tyrphostin RG14620 is an EGFR inhibitor of tyrphostin family, which selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.
CSN21355 Tyrphostin AG 528 133550-49-9 Tyrphostin is a potent inhibitor of EGFR protein tyrosine kinase.
CSN20011 Theliatinib 1353644-70-8 Theliatinib, is a small molecule, epidermal growth factor receptor tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenesis activities.
CSN20156 Pyrotinib dimaleate 1397922-61-0 Pyrotinib maleate is an irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with HER2-Positive metastatic breast cancer.
CSN19258 Mavelertinib 1776112-90-3 PF-06747775 provides potent EGFR activity against the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del), selectivity over wild-type EGFR, and desirable ADME properties.
CSN22485 PF-06459988 1428774-45-1 PF-06459988 is an irreversible inhibitor of T790M-Containing EGFR Mutants.
CSN23039 PF-6274484 1035638-91-5 PF 6274484 is a high affinity and potent covalent EGFR kinase inhibitor with Ki of 0.14 nM.
CSN16908 PD168393 194423-15-9 PD168393 is an inhibitor that targets EGFR with IC50 of 0.70 nM irreversibly. It is not active against insulin, PDGFR, FGFR and PKC.
CSN19270 AZD9291 Dimesylate N/A Osimertinib Dimesylate is a potent and selective mutated forms EGFR inhibitor (Exon 19 deletion EGFR IC50 =12.92 nM, L858R/T790M EGFR IC50 = 11.44 nM, wild type EGFR IC50 = 493.8 nM).
CSN16873 N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine 1421372-66-8 Osimertinib DA is a desacryl analogue of Osimertinib, is an intermediate inhibitor of mutated EGFR, including L858R EGFR, Exonl9 deletion and T790M resistance mutant.
CSN17738 Olmutinib 1353550-13-6 Olmutinib inhibits EGFR with IC50 values of 9.2 nM and 10 nM in HCC827 (expressing EGFR-del 19) and H1975 (expressing EGFR-L858R/T790M) cell respectively. It is a new targeted drug for the treatment of mutation-positive NSCLC.
CSN19011 Naquotinib mesylate 1448237-05-5 Naquotinib mesylate is a mutant-selective irreversible EGFR inhibitor with IC50 of 70 nM for NCI-H1650 cell growth,inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations.
CSN19010 Naquotinib 1448232-80-1 Naquotinib is an irreversible mutant EGFR inhibitor with potential antineoplastic activity.
CSN17827 Mutant EGFR inhibitor 1421373-62-7 Mutant EGFR inhibitor is a selective and potent Mutated EGFR inhibitor (L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant).
CSN21195 Lazertinib 1903008-80-9 Lazertinib is a selective inhibitor of mutant EGFR with lowest activity against EGFR wild type.
CSN18360 N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine 610798-31-7 Icotinib is an EGFR inhibitor with IC50 of 5 nM. EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R) are also its targets.
CSN18651 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one 446-72-0 Genistein has multiple biological functions. It can inhibit several tyrosine kinases (IC50 of 0.6 μM for EGFR), inhibits DNA topoisomerase-II and activation of PPARs. Genistein is a phytoestrogen which has selective estrogen receptor modulator properties.
CSN18050 Gefitinib HCl 184475-55-6 Gefitinib HCl is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.
CSN18153 Erlotinib mesylate 248594-19-6 Erlotinib mesylate is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM.
CSN16725 N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride   183319-69-9 Erlotinib HCl is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM.
CSN22392 EGFR-IN-2 1643497-70-4 EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor.
CSN19009 Nazartinib S-enantiomer 1508256-20-9 EGF816 S-Enantiomer is the S-enantiomer of EGF816.
CSN17903 Nazartinib mesylate 1508250-72-3 EGF816 mesylate is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min−1 on EGFR(L858R/790M) mutant, respectively.
CSN16199 Nazartinib 1508250-71-2 EGF816 inhibits mutant EGFR (L858R/790M) with Ki of 31 nM irreversibly and selectively.
CSN18738 2-(5-Fluoro-2-hydroxyphenyl)-2-(1-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide 1942114-09-1 EAI045, an allosteric inhibitor, selectively targets drug-resistant EGFR mutants like EGFR-L858R, EGFR-T790M and EGFR-L858R/T790M with IC50 of 0.019 μM, 0.19 μM and 0.002 μM respectively.
CSN19954 Cyasterone 17086-76-9 Cyasterone is an inhibitor of EGFR that maybe a promising anti-cancer agent espcially in skin carcinoma.
CSN17871 Rociletinib HBr 1446700-26-0 CO-1686 hydrobromide is an irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M (IC50=21 nM).
CSN17167 CNX-2006 1375465-09-0 CNX-2006 is an irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
CSN16222 CL-387785 194423-06-8 CL-387785 irreversibly inhibits EGFR with IC50 of 370 pM and shows inhibition of the functional effects of mutations T790M.
CSN18858 CHMFL-EGFR-202 2089381-40-6 CHMFL-EGFR-202 can form a covalent bond with Cys797 in a distinct "DFG-in-C-Helix-out" inactive EGFR conformation.
CSN25283 CGP52411 145915-58-8 CGP 52411 inhibited the EGF-R protein-tyrosine kinase in vitro with high selectivity. In cells, CGP52411 selectively inhibited both ligand-induced EGF-R and p185c-erbB2 autophosphorylation and c-fos mRNA induction.
CSN10535 Canertinib dihydrochloride 289499-45-2 Canertinib 2HCl, an irreversible quinazoline-based HER family tyrosine kinase inhibitor, inhibits EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM respectively. Phase II.
CSN18515 BMS-599626 HCl 873837-23-1 BMS-599626 is an inhibitor of HER1 (IC50 = 20 nM) and HER2 (IC50 = 30 nM).
CSN16872 (R)-4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate 1626387-80-1 AZD3759 is an inhibitor of EGFR (WT), EGFR (L858R) and EGFR (exon 19 deletion) (IC50s values are 0.3 nM, 0.2 nM and 0.2 nM, respectively).
CSN20594 Avitinib 1557267-42-1 Avitinib selectively inhibits EGFR L858R/T790M mutant with IC50 of 7.68 nM. It used as antineoplastic drug candidate.
CSN20602 N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide maleate 1557268-88-8 Avitinib maleate, the maleate salt form of avitinib, selectively inhibits EGFR L858R/T790M mutant with IC50 of 7.68 nM. It used as antineoplastic drug candidate.
CSN16123 N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)quinazolin-6-yl)acrylamide 451492-95-8 AV-412 is an inhibitor of EGFR (IC50 = 0.5-2 nM), ErbB2 (IC50=19 nM), Abl receptor (IC50 = 41nM), mutant EGFR-L858R (IC50=0.51 nM) and EGFR-T790M (IC50=0.79 nM). It also inhibits autophosphorylation of EGFR and ErbB2 with IC50s of 43 nM and 282 nM, respectively.
CSN16948 AV-412 451493-31-5 AV-412 is a potent dual inhibitor of EGFR and ErbB2(IC50=19 nM) tyrosine kinases, including the mutant EGFR(L858R IC50=0.51 nM, T790M IC50=0.79 nM). It inhibits autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM.
CSN24797 N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide methanesulfonate   2130958-55-1 AST2818 mesylate is an EGFR inhibitor.
CSN21203 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)cyclopropanamine dihydrochloride 1360460-82-7 Anlotinib is an inhibitor of receptor tyrosine kinase (RTK), including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3), and shows antineoplastic and anti-angiogenic activities.
CSN17439 Anlotinib 1058156-90-3 Anlotinib is an EGFR inhibitor which can be used to treat non-small cell lung cancer.
CSN24709 AG1557 189290-58-2 AG1557 is a specific EGFR tyrosine kinase inhibitor with pIC50 value of 8.194.
CSN21119 AG 494 133550-35-3 AG-494 is an inhibitor of EGFR with an IC50 value of 0.7 µM and it is inactive toward ErbB2, PDGFR and insulin receptor kinase.
CSN23735 (E)-AG 99 122520-85-8 AG 99 is an EGF receptor kinase inhibitor with IC50 of 10 µM in the human epidermoid carcinoma cell line A431.
CSN21882 AG 555 133550-34-2 AG 555 is an inhibitor of epidermal growth factor receptor (EGFR) with IC50 of 0.7 μM.
CSN16035 Afatinib dimaleate 850140-73-7 Afatinib dimaleate is an irreversible inhibitor of EGFR and HER2, the IC50s for EGFR (wt), EGFR (L858R), EGFR (L858R/T790M) and HER2 are 0.5 nM, 0.4 nM, 10 nM and 14 nM respectively.
<< PREV 1 2 3 4 NEXT >>
联系
我们